|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MHC class I-negative lymphoma cells (Daudi) were labelled with a biotinylated mAb specific for a cell surface protein (anti-CD20) then linked to soluble biotinylated HLA-A2/gag complexes using an avidin bridge.
|
10737389 |
2000 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results, further supported by gene set enrichment analyses in a clinical data set of chronic lymphocytic leukemia patient samples exposed to a rituximab-containing treatment regimen, provide important mechanistic insights into the biologic complexity of anti-CD20-evoked tumor responses, and unveil cellular senescence as a hitherto unrecognized effector principle of the antibody component in lymphoma immunochemotherapy.
|
26880268 |
2016 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20 Abs induce clinical responses in lymphoma patients, but there are considerable differences between individual patients.
|
11067958 |
2000 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination treatment with 4-1BBL/anti-CD20 fusion protein and anti-CD3/anti-CD20 diabody led to significantly increased T-cell cytotoxicity to human B-lymphoma cells in vitro and drastically more potent tumor inhibitory activity in vivo in xenografted B-cell lymphoma in severe combined immunodeficiency disease mice.
|
20463597 |
2010 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bispecific antibody (CD20-CD47SL) fusion of anti-CD20 (Rituximab) and anti-CD47 also demonstrated a synergistic effect against lymphoma in preclinical models.
|
29709247 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe 2 elderly patients with Human herpesvirus 8 (HHV-8)/Kaposi sarcoma herpes virus negative malignant effusion lymphoma showing pan-B-cell immunophenotyping markers and successfully treated with a chimeric anti-CD20 IgG1 monoclonal antibody, rituximab.
|
15621832 |
2005 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High avidity T-cell clones were identified that readily recognized and lysed primary HLA-A2pos B-cell leukemia and lymphoma in the absence of reactivity against CD20-negative but HLA-A2pos healthy hematopoietic and nonhematopoietic cells.
|
27776339 |
2016 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 14 patients with high-risk CD20+ lymphoma underwent an autologous peripheral blood stem cell transplantation (APBSCT).
|
16923109 |
2006 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
|
22689689 |
2012 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that 10 mg/mL rituximab saturated 80-95% of CD20 molecules per cell in all tested lymphoma samples.
|
11801463 |
2002 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is known for some time that the immune cell composition of the lymphoma microenvironment is important because high numbers of tissue-infiltrating macrophages correlate with poor outcome in patients receiving chemotherapy but not in patients receiving the combination of chemotherapy and CD20-specific monoclonal antibody rituximab.
|
29974035 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD20-positive T-cell lymphoma is a very rare type of lymphoma that is refractory to CHOP-like regimens alone.
|
29561444 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated combination therapy of IL-15 with rituximab in a syngeneic mouse model of lymphoma transfected with human CD20 and with alemtuzumab (Campath-1H) in a xenograft model of human adult T cell leukemia (ATL).
|
30373815 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab is an anti-CD20 antibody used to deplete B lymphocytes in lymphoma and autoimmune disease.
|
29561469 |
2018 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma.
|
30273194 |
2018 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)-associated systemic toxicity in the host.
|
28533311 |
2017 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A patient with fibrosing alveolitis developed a diffuse large B-cell (DLBC) lymphoma that expressed CD20 and CD30.
|
15257558 |
2004 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human/mouse chimeric CD20 antibody rituximab has significantly improved the survival of lymphoma patients.
|
21658620 |
2011 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of rituximab to salvage therapy before ASCT appears to improve the response rate, transplantation rate, and overall survival in patients with CD20+ lymphoma who responded to R-CHOP.
|
27266754 |
2017 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was composed of predominantly CD3-positive lymphocytes with scattered CD56-positive cells and CD20-positive cells, concerning for lymphoma.
|
23563253 |
2013 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stromal-cell coculture protects lymphoma cells from apoptosis in response to treatment with the CD20-targeted Ab rituximab.
|
22186993 |
2012 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The lymphoma cell was positive for CD20 and T cell lineage markers such as cytoplasmic CD3, CD4, and CD5 and had a monoclonal rearrangement of the T cell receptor (TCR) gamma chain gene.
|
11475154 |
2001 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma.
|
28614910 |
2017 |
|
Adult Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD20CAR-T cells responded efficiently to CD20-downregulated lymphoma and leukemia targets, including rituximab- or ofatumumab-refractory primary chronic lymphocytic leukemia cells.
|
25520398 |
2015 |
|
Adult Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A phase I study of recombinant human (rh) IL-18 given with ofatumumab was undertaken in patients with CD20 lymphoma who had undergone high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
|
29517616 |
2018 |